Cargando…

Biological markers of disease activity in inflammatory bowel diseases

Inflammatory bowel diseases (IBD) are chronic intestinal conditions of multifactorial aetiology including genetic susceptibility, immunological impairment, dysbiosis, and environmental factors. The diagnosis is based on both clinical and endoscopic features, wherein histopathological evaluation rema...

Descripción completa

Detalles Bibliográficos
Autores principales:	Szymanska, Edyta, Szymanska, Sylwia, Dadalski, Maciej, Kierkus, Jaroslaw
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Termedia Publishing House 2023
Materias:	Review Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10395055/ https://www.ncbi.nlm.nih.gov/pubmed/37538284 http://dx.doi.org/10.5114/pg.2023.129412

Ejemplares similares

Fecal Zonulin as a Noninvasive Biomarker of Intestinal Permeability in Pediatric Patients with Inflammatory Bowel Diseases—Correlation with Disease Activity and Fecal Calprotectin
por: Szymanska, Edyta, et al.
Publicado: (2021)

The impact of induction therapy with three doses of infliximab on deep histological healing in paediatric patients with active Crohn’s disease
por: Szymanska, Edyta, et al.
Publicado: (2016)

Safety profile of biologic therapy in Polish paediatric patients with Crohn's disease
por: Szymanska, Edyta, et al.
Publicado: (2015)

Adalimumab for endoscopic and histopathological mucosal healing in paediatric patients with moderate to severe Crohn’s disease
por: Szymanska, Edyta, et al.
Publicado: (2016)

Inflammatory bowel disease – one entity with many molecular faces
por: Szymańska, Sylwia, et al.
Publicado: (2019)

Profile of infliximab in the treatment of pediatric Crohn’s disease
por: Kierkus, Jaroslaw, et al.
Publicado: (2015)

Sexual functions in individuals with inflammatory bowel diseases
por: Kotkowicz-Szczur, Marta, et al.
Publicado: (2023)

The risk of cardiovascular complications in inflammatory bowel disease
por: Czubkowski, Piotr, et al.
Publicado: (2020)

Safety and Effectiveness of Vedolizumab for the Treatment of Pediatric Patients with Very Early Onset Inflammatory Bowel Diseases
por: Fabiszewska, Sylwia, et al.
Publicado: (2021)

Demographic characteristics of children with early clinical manifestation of inflammatory bowel disease
por: Szymańska, Edyta, et al.
Publicado: (2015)

Premedication Does Not Influence the Incidence of Infliximab Infusion Reactions in Pediatric Patients with Inflammatory Bowel Disease—A Single Center Case–Control Study
por: Szymanska, Edyta, et al.
Publicado: (2021)

The level of faecal calprotectin as a noninvasive biomarker of mucosal healing in children with ulcerative colitis
por: Szymańska, Edyta, et al.
Publicado: (2020)

Biosimilar biological drugs in the treatment of inflammatory bowel diseases
por: Kaniewska, Magdalena, et al.
Publicado: (2019)

Usefulness of Colon Assessment by Magnetic Resonance Enterography in Pediatric Patients with Inflammatory Bowel Disease—Retrospective Case Series
por: Sieczkowska-Golub, Joanna, et al.
Publicado: (2021)

Dual Biologic Therapy for the Treatment of Pediatric Inflammatory Bowel Disease: A Review of the Literature
por: Wlazło, Magdalena, et al.
Publicado: (2022)

Oral exclusive enteral nutrition for induction of clinical remission, mucosal healing, and improvement of nutritional status and growth velocity in children with active Crohn’s disease – a prospective multicentre trial
por: Matuszczyk, Małgorzata, et al.
Publicado: (2021)

Supplementation of Bovine Colostrum in Inflammatory Bowel Disease: Benefits and Contraindications
por: Sienkiewicz, Michał, et al.
Publicado: (2020)

Biosimilars in paediatric inflammatory bowel disease
por: Sieczkowska-Golub, Joanna, et al.
Publicado: (2018)

Dual Biologic Therapy in Moderate to Severe Pediatric Inflammatory Bowel Disease: A Retrospective Study
por: Wlazło, Magdalena, et al.
Publicado: (2022)

The importance of anti-transglutaminase IgA antibody detection in the diagnosis of celiac disease – case report of an inappropriate diagnostic approach
por: Szymańska, Edyta, et al.
Publicado: (2015)

Predictors and Early Markers of Response to Biological Therapies in Inflammatory Bowel Diseases
por: Privitera, Giuseppe, et al.
Publicado: (2021)

Serological markers of inflammatory bowel disease
por: Kuna, Andrea Tešija
Publicado: (2013)

Unexpected Actors in Inflammatory Bowel Disease Revealed by Machine Learning from Whole-Blood Transcriptomic Data
por: Nowak, Jan K., et al.
Publicado: (2022)

Insolation and Disease Severity in Paediatric Inflammatory Bowel Disease—A Multi-Centre Cross-Sectional Study
por: Glapa-Nowak, Aleksandra, et al.
Publicado: (2020)

Management of anemia in inflammatory bowel disease: a challenge in everyday clinical practice
por: Tulewicz-Marti, Edyta, et al.
Publicado: (2017)

Variable clinical presentation of glycogen storage disease type IV: from severe hepatosplenomegaly to cardiac insufficiency. Some discrepancies in genetic and biochemical abnormalities
por: Szymańska, Edyta, et al.
Publicado: (2017)

Immunogenicity of biologics in inflammatory bowel disease
por: Vermeire, Séverine, et al.
Publicado: (2018)

Autoimmune markers in children with chronic pancreatitis
por: Oracz, Grzegorz, et al.
Publicado: (2014)

C-Reactive Protein/Albumin Ratio at Diagnosis of Pediatric Inflammatory Bowel Disease: A Retrospective Multi-Center Study
por: Glapa-Nowak, Aleksandra, et al.
Publicado: (2022)

Biologic targeting in the treatment of inflammatory bowel diseases
por: Bosani, Matteo, et al.
Publicado: (2009)

Nutritional Therapy in Pediatric Crohn’s Disease—Are We Going to Change the Guidelines?
por: Matuszczyk, Malgorzata, et al.
Publicado: (2021)

Over 20-Year Follow-up of Patients with Hepatic Glycogen Storage Diseases: Single-Center Experience
por: Szymańska, Edyta, et al.
Publicado: (2020)

Metabolic dysfunction-associated steatotic liver disease as a cardiovascular risk factor
por: Platek, Anna E., et al.
Publicado: (2023)

Genetic Variants of DMBT1 and SFTPD and Disease Severity in Paediatric Inflammatory Bowel Disease—A Polish Population-Based Study
por: Glapa-Nowak, Aleksandra, et al.
Publicado: (2021)

Diagnostic Markers for Nonspecific Inflammatory Bowel Diseases
por: Derkacz, Alicja, et al.
Publicado: (2018)

The Essential Role of microRNAs in Inflammatory and Autoimmune Skin Diseases—A Review
por: Dopytalska, Klaudia, et al.
Publicado: (2023)

Costs in inflammatory bowel diseases
por: Petryszyn, Paweł W., et al.
Publicado: (2016)

Outcomes of oral biotin treatment in patients with biotinidase deficiency — Twenty years follow-up
por: Szymańska, Edyta, et al.
Publicado: (2015)

Is there an optimal sequence of biologic therapies for inflammatory bowel disease?
por: Bressler, Brian
Publicado: (2023)

Relationship between the Biological Clock and Inflammatory Bowel Disease
por: Giebfried, Jonathan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_rlugh0shrfilqtq7lsup5rs63k